BRANFORD, Conn., May 18, 2021 /PRNewswire/ -- IsoPlexis, the
leader in single-cell proteomics, today announced an exclusive
agreement with Bucher Biotec AG, a Swiss distributor company
representing some of the most advanced US, European, and Asian
manufacturers of highly innovative life science research
instrumentation, associated reagents, and consumables. This
agreement follows IsoPlexis' recent global distributor
announcements, throughout Asia and
Europe.
IsoPlexis' IsoLight platform has received numerous awards,
recognized as both The Scientist's and Fierce Life Science's #1
innovation for the ability to provide single-cell sensitivity with
highly multiplexed and quantitative functional ELISA detection
together for the first time. IsoPlexis' IsoLight was awarded the
global Red Dot Design Award for its ease of use, and the 18-inch
IsoSpark system has received two Red Dot Design Awards for High
Design Quality & Innovative Product. These systems are now
available to customers in Singapore, Malaysia, China, Taiwan, Japan, South
Korea, Spain, Portugal, and Switzerland through IsoPlexis' latest
agreements.
Bucher Biotec strives to provide the highest standards for their
customers, with a distinguished customer base in the pharmaceutical
and biotechnology industries as well as life science
research-oriented academic institutions and clinical labs.
"We are excited to partner with Bucher Biotec to further expand
the reach of our unique solutions," said Peter Siesel, Chief Commercial Officer. "Our
functional proteomics platform accelerates the development of
personalized, curative medicines across a range of diseases and
research disciplines. With this partnership, we are excited to see
our usership grow even further."
ABOUT BUCHER BIOTEC AG:
Bucher Biotec AG is a privately held Swiss distributor company,
founded in 1978, representing some of the most advanced US,
European, and Asian manufacturers of highly innovative life science
research instrumentation, associated reagents, and consumables. We
are extremely proud of our distinguished customer base in the
pharmaceutical, biotechnology, agricultural, food and related
industries, in all life science research-oriented academic
institutions, in numerous governmental, clinical, and environmental
labs, and in all of the university hospitals. Our highly competent,
well-educated team is focused on understanding our customer's needs
in order to propose optimal solutions for demanding research tasks
enabling the acceleration of scientific exploration. We can easily
be reached via http://www.bucher.ch
ABOUT ISOPLEXIS:
IsoPlexis is a life science technology company building
solutions to accelerate the development of curative medicines and
personalized therapeutics. Our award-winning single-cell proteomics
systems reveal unique biological activity in small subsets of
cells, allowing researchers to connect more directly to in
vivo biology and develop more precise and personalized
therapies. Our integrated systems, named top innovation or design
by the Scientist Magazine, Fierce, BIG Innovation, Red Dot &
multiple others, are used globally to advance the field of
single-cell biology into new 'omic possibilities, as our customers
generate solutions to overcome the challenges of complex diseases
and therapeutics. Our products have been adopted by
researchers around the world, including the top 15 global
pharmaceutical companies and by 45% of comprehensive cancer centers
in the U.S.. Visit http://www.isoplexis.com to learn more.
MEDIA CONTACT:
Jon Chen
VP of Marketing
IsoPlexis
press@isoplexis.com
SOURCE IsoPlexis
Related Links
http://www.isoplexis.com
http://www.bucher.ch
View original content to download
multimedia:http://www.prnewswire.com/news-releases/isoplexis-partners-with-bucher-biotec-to-expand-into-switzerland-market-301293182.html
SOURCE IsoPlexis